Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,

Published byAmber Harmon Modified over 8 years ago

Similar presentations

Presentation on theme: "Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,"— Presentation transcript:

1 Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD, Lynne W. Stevenson, MD, Elizabeth D. Blume, MD, Marissa A. Miller, DVM, MPH, J.T. Baldwin, PhD, James B. Young, MD The Journal of Heart and Lung Transplantation Volume 33, Issue 6, Pages 555-564 (June 2014) DOI: 10.1016/j.healun.2014.04.010 Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

2 Figure 1 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

3 Figure 2 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

4 Figure 3 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

5 Figure 4 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

6 Figure 5 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

7 Figure 6 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

8 Figure 7 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

9 Figure 8 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

10 Figure 9 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

11 Figure 10 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

12 Figure 11 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

13 Figure 12 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

14 Figure 13 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

15 Figure 14 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

16 Figure 15 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

17 Figure 16 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

18 Figure 17 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

19 Figure 18 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

20 Figure 19 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

21 Figure 20 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

22 Figure 21 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

23 Figure 22 The Journal of Heart and Lung Transplantation 2014 33, 555-564DOI: (10.1016/j.healun.2014.04.010) Copyright © 2014 International Society for Heart and Lung Transplantation Terms and Conditions Terms and Conditions

Download ppt "Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,"

Similar presentations

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.
ABO-incompatible heart transplantation in early childhood: An international multicenter study of clinical experiences and limits Simon Urschel, MD, Ingrid.

ABO-incompatible heart transplantation in early childhood: An international multicenter study of clinical experiences and limits Simon Urschel, MD, Ingrid.
Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.

Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.
California Pertussis Epidemic, 2010 Kathleen Winter, MPH, Kathleen Harriman, PhD, MPH, RN, Jennifer Zipprich, PhD, Robert Schechter, MD, John Talarico,

California Pertussis Epidemic, 2010 Kathleen Winter, MPH, Kathleen Harriman, PhD, MPH, RN, Jennifer Zipprich, PhD, Robert Schechter, MD, John Talarico,
Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,

Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,
Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I

Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I
Effect of high-intensity interval training on progression of cardiac allograft vasculopathy  Kari Nytrøen, PhDc, Lene Annette Rustad, MD, Ingrid Erikstad,

Effect of high-intensity interval training on progression of cardiac allograft vasculopathy  Kari Nytrøen, PhDc, Lene Annette Rustad, MD, Ingrid Erikstad,
Management of Anticoagulation in Patients with Mechanical Circulatory Support Using a Physician-Based Versus a Pharmacist Directed Anticoagulation Clinic-Based.

Management of Anticoagulation in Patients with Mechanical Circulatory Support Using a Physician-Based Versus a Pharmacist Directed Anticoagulation Clinic-Based.
Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation  Kathleen L. Grady, PhD, RN, David C. Naftel, PhD,

Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation  Kathleen L. Grady, PhD, RN, David C. Naftel, PhD,
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation 

De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation 
The Journal of Heart and Lung Transplantation

The Journal of Heart and Lung Transplantation
The Epidemic of the 20th Century: Coronary Heart Disease

The Epidemic of the 20th Century: Coronary Heart Disease
T. Oyaizu, S.-Y. Fung, A. Shiozaki, B. Han, S. Keshavjee, M. Liu 

T. Oyaizu, S.-Y. Fung, A. Shiozaki, B. Han, S. Keshavjee, M. Liu 
Hypertension-Lipid Connection: Introduction

Hypertension-Lipid Connection: Introduction
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.

Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
Jennifer A. Cowger, MD, Matthew A

Jennifer A. Cowger, MD, Matthew A
The Journal of Heart and Lung Transplantation

The Journal of Heart and Lung Transplantation

Similar presentations

Ads by Google